Background: There is currently no evidence that hepatitis C virus (HCV) genotype affects survival in patients with\nhepatocellular carcinoma (HCC). This study aimed to investigate whether the HCV genotype affected the survival\nrate of patients with HCV-related HCC.\nMethods: We performed a retrospective cohort study using the data of patients with HCV-related HCC evaluated at\ntwo centers in Korea between January 2005 and December 2016. Propensity score matching between genotype 2\npatients and non-genotype 2 patients was performed to reduce bias.\nResults: A total of 180 patients were enrolled. Of these, 86, 78, and 16 had genotype 1, genotype 2, and genotype\n3 HCV-related HCC, respectively. The median age was 66.0 years, and the median overall survival was 28.6 months.\nIn the entire cohort, patients with genotype 2 had a longer median overall survival (31.7 months) than patients with\ngenotype 1 (28.7 months; P = 0.004) or genotype 3 (15.0 months; P = 0.003). In the propensity score-matched\ncohort, genotype 2 patients also showed a better survival rate than non-genotype 2 patients (P = 0.007). Genotype\n2 patients also had a longer median decompensation-free survival than non-genotype 2 patients (P = 0.001).\nHowever, there was no significant difference in recurrence-free survival between genotype 2 and non-genotype 2\npatients who underwent curative treatment (P = 0.077). In multivariate Cox regression analysis, non-genotype 2\n(hazard ratio, 2.19; 95% confidence interval, 1.29-3.71) remained an independent risk factor for death.\nConclusion: Among patients with HCV-related HCC, those with genotype 2 have better survival.
Loading....